ABIVAX Société Anonyme (NASDAQ:ABVX) Earns Buy Rating from Analysts at Guggenheim

Guggenheim started coverage on shares of ABIVAX Société Anonyme (NASDAQ:ABVX) in a research report sent to investors on Monday, MarketBeat reports. The firm issued a buy rating and a $50.00 price target on the stock.

Separately, Morgan Stanley upped their price target on shares of ABIVAX Société Anonyme from $15.00 to $16.00 and gave the stock an equal weight rating in a research report on Thursday, April 11th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, ABIVAX Société Anonyme presently has an average rating of Moderate Buy and a consensus price target of $32.00.

ABIVAX Société Anonyme Stock Up 0.3 %

NASDAQ:ABVX opened at $15.04 on Monday. The firm has a 50 day moving average price of $14.57. ABIVAX Société Anonyme has a 1-year low of $7.99 and a 1-year high of $17.02.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ABVX. Capstone Investment Advisors LLC lifted its position in shares of ABIVAX Société Anonyme by 9.0% in the 1st quarter. Capstone Investment Advisors LLC now owns 62,966 shares of the company’s stock worth $900,000 after buying an additional 5,199 shares during the last quarter. BNP Paribas Financial Markets bought a new position in shares of ABIVAX Société Anonyme in the 1st quarter worth about $81,000. Ghisallo Capital Management LLC bought a new position in shares of ABIVAX Société Anonyme in the 4th quarter worth about $642,000. Rosalind Advisors Inc. bought a new position in shares of ABIVAX Société Anonyme in the 1st quarter worth about $5,411,000. Finally, Franklin Resources Inc. bought a new position in shares of ABIVAX Société Anonyme in the 4th quarter worth about $13,630,000. 47.91% of the stock is owned by institutional investors and hedge funds.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.